Asthma remission: what is it and how can it be achieved?

Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyper-responsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments.

[1]  R. Chaudhuri,et al.  Biologics in severe asthma: Which one, When and Where? , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  W. Carr,et al.  Exacerbations in US Severe Asthma: Incidence, Characteristics, Predictors, and Effects of Biologic Treatments. , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  J. Upham,et al.  Defining a severe asthma super-responder: findings from a Delphi process. , 2021, The journal of allergy and clinical immunology. In practice.

[4]  M. Humbert,et al.  Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) , 2021, European Respiratory Journal.

[5]  U. Walker,et al.  Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. , 2021, Rheumatology.

[6]  C. Jenkins,et al.  Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. , 2021, The journal of allergy and clinical immunology. In practice.

[7]  I. Pavord,et al.  Dupilumab Treatment Leads to Clinical Asthma Remission in Patients With Uncontrolled Moderate-to-Severe Asthma With Type 2 Inflammation , 2021, Journal of Allergy and Clinical Immunology.

[8]  Shih-Lung Cheng Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways , 2021, Diagnostics.

[9]  C. Ulrik,et al.  Remission and changes in severity over 30 years in an adult asthma cohort. , 2020, The journal of allergy and clinical immunology. In practice.

[10]  W. Busse,et al.  How Do Asthma Biologics Relate to Remission for Asthma? , 2020, The journal of allergy and clinical immunology. In practice.

[11]  A. Agustí,et al.  TREATABLE TRAITS THAT PREDICT HEALTH STATUS AND TREATMENT RESPONSE IN AIRWAY DISEASE. , 2020, The journal of allergy and clinical immunology. In practice.

[12]  A. Lindberg,et al.  Remission of adult-onset asthma is rare: a 15-year follow-up study , 2020, ERJ Open Research.

[13]  E. Israel,et al.  A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER) , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  I. Dávila,et al.  Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A consensus statement. , 2020, Journal of investigational allergology & clinical immunology.

[15]  I. Du Rand,et al.  British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease , 2020, Thorax.

[16]  A. Nanzer,et al.  Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.

[17]  C. Jenkins,et al.  Mepolizumab effectiveness and identification of super-responders in severe asthma , 2020, European Respiratory Journal.

[18]  K. Sladek,et al.  Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics , 2020, The Journal of asthma : official journal of the Association for the Care of Asthma.

[19]  I. Pavord,et al.  An Expert Consensus Framework for Asthma Remission as a Treatment Goal. , 2019, The Journal of allergy and clinical immunology.

[20]  P. Gibson,et al.  Targeting treatable traits in severe asthma: a randomised controlled trial , 2019, European Respiratory Journal.

[21]  S. Hiles,et al.  Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis , 2019, European Respiratory Journal.

[22]  M. Cabana,et al.  Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline , 2019, European Respiratory Journal.

[23]  M. Nawijn,et al.  A review on the pathophysiology of asthma remission. , 2019, Pharmacology & therapeutics.

[24]  D. Aletaha,et al.  Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. , 2019, Rheumatology.

[25]  C. Jenkins,et al.  A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma. , 2019, The Journal of allergy and clinical immunology.

[26]  H. Ortega,et al.  Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.

[27]  W. Busse Biological treatments for severe asthma: A major advance in asthma care. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[28]  I. Pavord,et al.  Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report , 2019, European Respiratory Journal.

[29]  J. Krings,et al.  Role of Biologics in Asthma , 2019, American journal of respiratory and critical care medicine.

[30]  W. Busse,et al.  Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. , 2019, The journal of allergy and clinical immunology. In practice.

[31]  C. Jenkins,et al.  Treatable traits can be identified in a severe asthma registry and predict future exacerbations , 2018, Respirology.

[32]  C. Bai,et al.  The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema , 2018, Respiration.

[33]  Y. Bossé,et al.  Novel genes and insights in complete asthma remission: A genome‐wide association study on clinical and complete asthma remission , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[34]  T. Sigsgaard,et al.  Determinants of persistent asthma in young adults , 2018, European clinical respiratory journal.

[35]  K. Sladek,et al.  Influence of omalizumab therapy on airway remodeling assessed with high-resolution computed tomography (HRCT) in severe allergic asthma patients. , 2015, Advances in respiratory medicine.

[36]  E. Bel,et al.  Clinical predictors of remission and persistence of adult‐onset asthma , 2018, The Journal of allergy and clinical immunology.

[37]  E. Israel,et al.  Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.

[38]  C. Jenkins,et al.  Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[39]  T. Huizinga,et al.  Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations , 2017, Therapeutic advances in musculoskeletal disease.

[40]  D. Postma,et al.  Childhood factors associated with complete and clinical asthma remission at 25 and 49 years , 2017, European Respiratory Journal.

[41]  P. Emery,et al.  Modifying the trajectory of asthma—are there lessons from the use of biologics in rheumatology? , 2017, The Lancet.

[42]  G. Canonica,et al.  Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months , 2017, Clinical and Translational Allergy.

[43]  K. Rabe,et al.  Asthma transition from childhood into adulthood. , 2017, The Lancet. Respiratory medicine.

[44]  P. O'Byrne,et al.  Biologics and the lung: TSLP and other epithelial cell‐derived cytokines in asthma , 2017, Pharmacology & therapeutics.

[45]  C. Wagner,et al.  Airway remodeling in asthma: what really matters , 2017, Cell and Tissue Research.

[46]  O. Niemelä,et al.  A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study. , 2016, Respiratory medicine.

[47]  I. Pavord,et al.  Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.

[48]  R. de Marco,et al.  Seventy Years of Asthma in Italy: Age, Period and Cohort Effects on Incidence and Remission of Self-Reported Asthma from 1940 to 2010 , 2015, PloS one.

[49]  M. Tamm,et al.  Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab , 2015, PloS one.

[50]  D. Mungan,et al.  Prognosis of adult asthma: a 7-year follow-up study. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[51]  G. Canonica,et al.  Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. , 2014, Immunology letters.

[52]  P. Gibson,et al.  Full blood count parameters for the detection of asthma inflammatory phenotypes , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[53]  C. Robertson,et al.  Outcomes of childhood asthma to the age of 50 years. , 2014, The Journal of allergy and clinical immunology.

[54]  M. Bugiani,et al.  The Course of Asthma in Young Adults: A Population-Based Nine-Year Follow-Up on Asthma Remission and Control , 2014, PloS one.

[55]  M. Chan-yeung,et al.  Sustained Elevation of Systemic Oxidative Stress and Inflammation in Exacerbation and Remission of Asthma , 2013, ISRN allergy.

[56]  D. Serisier Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. , 2013, The Lancet. Respiratory medicine.

[57]  R. Luukkonen,et al.  Positive Exercise Test and Obstructive Spirometry in Young Male Conscripts Associated with Persistent Asthma 20 years Later , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[58]  G. Canonica,et al.  Omalizumab Modulates Bronchial Reticular Basement Membrane Thickness and Eosinophil Infiltration in Severe Persistent Allergic Asthma Patients , 2012, International journal of immunopathology and pharmacology.

[59]  M. Hoshino,et al.  Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma , 2012, Respiration.

[60]  L. Boulet,et al.  Airway function, inflammation and regulatory T cell function in subjects in asthma remission. , 2012, Canadian respiratory journal.

[61]  Margaret W Leigh,et al.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.

[62]  A. James,et al.  Remission of asthma: The next therapeutic frontier? , 2011, Pharmacology & therapeutics.

[63]  D. Postma,et al.  Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. , 2011, American journal of respiratory and critical care medicine.

[64]  P. Gibson,et al.  Multidimensional assessment of older people with asthma and COPD: clinical management and health status. , 2011, Age and ageing.

[65]  D. Postma,et al.  Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV(1). , 2010, Respiratory medicine.

[66]  K. Bønnelykke,et al.  Long-term studies of the natural history of asthma in childhood. , 2010, The Journal of allergy and clinical immunology.

[67]  Y. Goekoop-Ruiterman,et al.  Rheumatoid arthritis: Can we achieve true drug-free remission in patients with RA? , 2010, Nature Reviews Rheumatology.

[68]  H. Mochizuki,et al.  Relationship between bronchial hyperreactivity and asthma remission during adolescence. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[69]  L. Boulet Influence of comorbid conditions on asthma , 2009, European Respiratory Journal.

[70]  S. Dahlén,et al.  No further increase of incidence of asthma: incidence, remission and relapse of adult asthma in Sweden. , 2008, Respiratory medicine.

[71]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[72]  A. Lindberg,et al.  Outcome and severity of adult onset asthma--report from the obstructive lung disease in northern Sweden studies (OLIN). , 2007, Respiratory medicine.

[73]  L. Irving,et al.  The natural history of asthma from childhood to adulthood , 2007, International journal of clinical practice.

[74]  T. Gislason,et al.  Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study) , 2007, European Respiratory Journal.

[75]  John W. Wilson,et al.  Airway remodelling in asthma: current understanding and implications for future therapies. , 2006, Pharmacology & therapeutics.

[76]  Deborah Jarvis,et al.  Prognostic factors of asthma severity: a 9-year international prospective cohort study. , 2006, The Journal of allergy and clinical immunology.

[77]  H. Bisgaard,et al.  Intermittent inhaled corticosteroids in infants with episodic wheezing. , 2006, The New England journal of medicine.

[78]  Vernon M Chinchilli,et al.  Long-term inhaled corticosteroids in preschool children at high risk for asthma. , 2006, The New England journal of medicine.

[79]  H. Hoogsteden,et al.  Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. , 2005, Respiratory medicine.

[80]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[81]  D. Postma,et al.  Childhood factors associated with asthma remission after 30 year follow up , 2004, Thorax.

[82]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[83]  Phil A. Silva,et al.  A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. , 2003, The New England journal of medicine.

[84]  H. Hoogsteden,et al.  Asthma remission: does it exist? , 2003, Current opinion in pulmonary medicine.

[85]  A. Bush,et al.  Early thickening of the reticular basement membrane in children with difficult asthma. , 2003, American journal of respiratory and critical care medicine.

[86]  P. Phelan,et al.  The Melbourne Asthma Study: 1964-1999. , 2002, The Journal of allergy and clinical immunology.

[87]  P. Barnes,et al.  Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.

[88]  H. Hoogsteden,et al.  Airway inflammation is present during clinical remission of atopic asthma. , 2001, American journal of respiratory and critical care medicine.

[89]  J Bousquet,et al.  Asthma. From bronchoconstriction to airways inflammation and remodeling. , 2000, American journal of respiratory and critical care medicine.

[90]  H. Hoogsteden,et al.  Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. , 2000, American journal of respiratory and critical care medicine.

[91]  E. Rönmark,et al.  Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study , 1999, Thorax.

[92]  H. Maruo [The relapse rate in patients with bronchial asthma remission and the risk factors of relapse]. , 1999, Arerugi = [Allergy].

[93]  G. Crompton,et al.  Management of Severe Asthma , 1998 .

[94]  P. Emery,et al.  Early rheumatoid arthritis: time to aim for remission? , 1995, Annals of the rheumatic diseases.

[95]  L. Boulet,et al.  Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. , 1994, Chest.

[96]  P D Phelan,et al.  The natural history of childhood asthma to adult life. , 1980, British medical journal.